Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SG001 + PLD in platinum-resistant ovarian cancer
NCT04983550Phase 2Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Sep 2021
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of PBI-1308 in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Status: unknown.
02
Drugs
PBI-1308
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04983550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04983550.